Dr. Lal PathLabs Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LALPATHLAB.BO | 4694.T | 4544.T | LH | METROPOLIS.NS | DHR | |
|---|---|---|---|---|---|---|
| Market cap | 306.81B | 144.31B | 200.95B | 26.26B | 110.70B | 164.40B |
| P/E (TTM) | 56.7 | 18.5 | 21.8 | 26.8 | 55.0 | 41.7 |
| Forward P/E | 41.8 | 25.9 | 36.4 | 16.4 | 34.5 | 25.1 |
| Price/book | 12.2 | 1.1 | 1.5 | 3.0 | 7.3 | 3.1 |
| Dividend yield | 1.08% | 3.26% | 3.37% | 0.89% | 0.39% | 0.71% |
| 1-year change | +17.16% | +5.65% | −6.46% | +14.24% | +7.59% | +2.82% |
| Today | −0.49% | +0.39% | +0.27% | +0.19% | +2.79% | +4.29% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 20 min.
Latest news
All LALPATHLAB.BO news ›Dr. Lal Pathlabs rises as its arm acquires remaining 30% stake in Centrapath Labs
Mumbai, October 14 (Udaipur Kiran): Dr. Lal Pathlabs is currently trading at Rs. 1928.20, up by 16.70 points or 0.87% from its previous closing of Rs. 1911.50 on the BSE. The scrip opened at Rs. 1909.00 and has touched a high and low of…
Axis Direct bullish on Dr Lal PathLabs, Vijaya Diagnostic and Nephrocare, assigns 'Buy' ratings with up to 21% upside
Axis Direct is bullish on Dr Lal PathLabs, Vijaya Diagnostic Centre and Nephrocare Health Services, assigning 'Buy' ratings to all three stocks and setting target prices that imply an upside of up to 21%, citing structural growth drivers…
Dr. Lal PathLabs Invests Up To ₹30.3 Crore In Wholly Owned Subsidiary PUPL
Dr. Lal PathLabs has made a further investment of up to ₹30.3 crore in its wholly owned subsidiary, PathLabs Unifiers Private Limited (PUPL). The investment involves a cash consideration not exceeding ₹30.3 crore. PUPL will continue to…
Dr. Lal PathLabs invests up to INR 30.3 crore in PathLabs Unifiers
Dr. Lal PathLabs Limited, a prominent entity in the healthcare and diagnostics sector, has announced a further investment into its wholly owned subsidiary, PathLabs Unifiers Private Limited (PUPL). The investment, made by subscribing to…
Income Tax Dept. appeals against tax relief favouring Dr Lal PathLabs; stock falls 2.4%
Dr Lal PathLabs said the Income Tax Department has appealed to the ITAT against an earlier order granting the company relief on ₹32.66 crore in ESOP expenses for assessment year 2022-23. Dr Lal PathLabs Limited disclosed on Thursday that…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
thehindubusinessline.com4
-
tradingview.com4
-
moneycontrol.com2
-
business-standard.com1
-
businessupturn.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 19 articles, not a forecast.